Sarcoidosis and Polymethyl Methacrylate (PMMA) Granulomas following COVID-19 Vaccination (ChAdOx1): Successful Treatment with Tofacitinib

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorCório Clínica-
Autor(es): dc.contributorUniversidade Federal de Goiás (UFG)-
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.contributorHospital Einstein-
Autor(es): dc.creatorIanhez, Mayra-
Autor(es): dc.creatorMiot, Hélio A-
Autor(es): dc.creatorCaetano, Lívia V.N.-
Autor(es): dc.creatorDe Paula, Henrique Moura-
Autor(es): dc.creatorFreire, Giselle G.S.-
Autor(es): dc.creatorTorres, Pedro P.T.S.-
Data de aceite: dc.date.accessioned2025-08-21T19:49:06Z-
Data de disponibilização: dc.date.available2025-08-21T19:49:06Z-
Data de envio: dc.date.issued2025-04-29-
Data de envio: dc.date.issued2023-12-31-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.4103/ijd.ijd_56_24-
Fonte completa do material: dc.identifierhttps://hdl.handle.net/11449/306913-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/306913-
Descrição: dc.descriptionSarcoidosis and complications related to fillers have been reported following the COVID-19 vaccination. Additionally, cutaneous sarcoidosis has been observed around polymethyl methacrylate (PMMA) injection sites. Foreign-body reactions to PMMA can occur simultaneously with systemic sarcoidosis, suggesting a shared pathogenic mechanism between both conditions. To report a case of sarcoidosis and PMMA granulomas following COVID-19 vaccination (ChAdOx11), successfully treated with tofacitinib. We present a 59-year-old woman who developed systemic sarcoidosis and a granulomatous reaction to PMMA filler following the COVID-19 vaccination (ChAdOx11). Notably, both PMMA and the vaccine were potential triggers for sarcoidosis. Treatment with tofacitinib produced marked improvement in both the cutaneous and pulmonary involvement of sarcoidosis and the granulomatous reaction to PMMA. This successful outcome suggests tofacitinib, a pan-JAK inhibitor, an alternative treatment for cutaneous and systemic sarcoidosis, as well as a potential therapy for granulomatous complications of dermal fillers, such as PMMA.-
Descrição: dc.descriptionThe Department of Dermatology Cório Clínica, GO-
Descrição: dc.descriptionDepartment of Dermatology Universidade Federal de Goiás, GO-
Descrição: dc.descriptionDepartment of Dermatology Universidade Estadual Paulista Júlio de Mesquita Filho (UNESP), SP-
Descrição: dc.descriptionDepartment of Radiology Hospital Einstein, GO-
Descrição: dc.descriptionDepartment of Dermatology Universidade Estadual Paulista Júlio de Mesquita Filho (UNESP), SP-
Formato: dc.format328-332-
Idioma: dc.languageen-
Relação: dc.relationIndian Journal of Dermatology-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectAesthetic dermatology-
Palavras-chave: dc.subjectCOVID-19-
Palavras-chave: dc.subjectgranuloma-
Palavras-chave: dc.subjectJanus kinase inhibitors-
Palavras-chave: dc.subjectpolymethyl methacrylate-
Palavras-chave: dc.subjectsarcoidosis-
Título: dc.titleSarcoidosis and Polymethyl Methacrylate (PMMA) Granulomas following COVID-19 Vaccination (ChAdOx1): Successful Treatment with Tofacitinib-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.